EpCAM (CD326), a human cell surface glycoprotein that is 39–40 kDa in size and widely expressed in a variety of cancer cells, including ovarian, breast, colorectal, prostate, lung, and pancreatic, is one of the more alluring targets for immunotherapy. This evidence concerns the gene EPCAM and cancer.